maccura(SZ:300463)2025-05-11 12:32Group 1: Company Overview and Market Position - Mike Biotech Co., Ltd. is committed to enhancing investor value and strictly adheres to market value management regulations [2][3]. - The company has established a comprehensive market presence with 11 subsidiary channels and 23 offices, covering over 9,100 medical institutions [18]. Group 2: Financial Performance - In 2024, the company reported a revenue of CNY 2.549 billion and a net profit of CNY 127 million; for Q1 2025, revenue was CNY 510 million with a net profit of CNY 24 million [11][14]. - Cumulative cash dividends since listing amount to CNY 1.214 billion, with a proposed dividend of CNY 63 million for 2024, increasing the payout ratio to 50% of net profit [4]. Group 3: Value Management and Investor Relations - The company has implemented a value management system since March 2024, focusing on compliance and maximizing shareholder interests [3][4]. - From 2024 to Q1 2025, the company conducted over 200 investor interactions and issued four investor relations activity records [5][6]. Group 4: Challenges and Strategic Responses - The company faced a decline in performance due to goodwill impairment losses of CNY 94 million and market adjustments related to procurement policies [14][23]. - The IVD industry is experiencing significant pressure from policy changes, with over 70% of companies reporting revenue declines in 2024 [24]. Group 5: Future Outlook and Growth Strategies - The company aims to increase its overseas market share to 30% by 2030, with a projected overseas sales revenue of CNY 160 million in 2024, a 60% increase year-on-year [19][21]. - R&D investment for 2024 was CNY 419 million, representing 21.91% of revenue from self-developed products, focusing on automation and systematization [24].